Global Blood Therapeutics Inc. [GBT] moved up 41.44: Why It’s Important


Global Blood Therapeutics Inc. [NASDAQ: GBT] closed the trading session at $47.99 on 08/04/22. The day’s price range saw the stock hit a low of $43.53, while the highest price level was $48.49. The company report on August 4, 2022 that GBT Announces New Employment Inducement Grants.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units for an aggregate of 30,450 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.

The stocks have a year to date performance of 63.96 percent and weekly performance of 46.62 percent. The stock has been moved at 70.78 percent over the last six months. The stock has performed 43.30 percent around the most recent 30 days and changed 49.27 percent over the most recent 3-months.

If compared to the average trading volume of 1.54M shares, GBT reached to a volume of 8852630 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Global Blood Therapeutics Inc. [GBT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GBT shares is $59.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GBT stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wedbush have made an estimate for Global Blood Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 28, 2022. The new note on the price target was released on December 07, 2021, representing the official price target for Global Blood Therapeutics Inc. stock. Previously, the target price had yet another raise to $68, while Jefferies analysts kept a Buy rating on GBT stock.

The Average True Range (ATR) for Global Blood Therapeutics Inc. is set at 2.63, with the Price to Sales ratio for GBT stock in the period of the last 12 months amounting to 15.41. The Price to Book ratio for the last quarter was 23.18, with the Price to Cash per share for the same quarter was set at 8.17.

GBT stock trade performance evaluation

Global Blood Therapeutics Inc. [GBT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 46.62. With this latest performance, GBT shares gained by 43.30% in over the last four-week period, additionally plugging by 70.78% over the last 6 months – not to mention a rise of 48.76% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GBT stock in for the last two-week period is set at 82.76, with the RSI for the last a single of trading hit 88.03, and the three-weeks RSI is set at 77.89 for Global Blood Therapeutics Inc. [GBT]. The present Moving Average for the last 50 days of trading for this stock 30.29, while it was recorded at 35.99 for the last single week of trading, and 30.67 for the last 200 days.

Global Blood Therapeutics Inc. [GBT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Global Blood Therapeutics Inc. [GBT] shares currently have an operating margin of -147.72 and a Gross Margin at +93.87. Global Blood Therapeutics Inc.’s Net Margin is presently recorded at -155.63.

Return on Equity for this stock declined to -98.96, with Return on Assets sitting at -36.45.

Global Blood Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 8.50.

Earnings per share (EPS) analysis for Global Blood Therapeutics Inc. [GBT] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GBT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Global Blood Therapeutics Inc. go to 37.00%.

Global Blood Therapeutics Inc. [GBT]: Insider Ownership positions

There are presently around $3,407 million, in the hands of institutional investors. The top three institutional holders of GBT stocks are: VANGUARD GROUP INC with ownership of 6,024,262, which is approximately 0.519% of the company’s market cap and around 1.90% of the total institutional ownership; JANUS HENDERSON GROUP PLC, holding 5,603,255 shares of the stock with an approximate value of $268.9 million in GBT stocks shares; and BLACKROCK INC., currently with $253.6 million in GBT stock with ownership of nearly -1.28% of the company’s market capitalization.

Positions in Global Blood Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 109 institutional holders increased their position in Global Blood Therapeutics Inc. [NASDAQ:GBT] by around 10,144,093 shares. Additionally, 100 investors decreased positions by around 5,426,277 shares, while 31 investors held positions by with 55,419,651 shares. The mentioned changes placed institutional holdings at 70,990,021 shares, according to the latest SEC report filing. GBT stock had 33 new institutional investments in for a total of 2,632,396 shares, while 31 institutional investors sold positions of 3,515,733 shares during the same period.